A:NYE-Agilent Technologies Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 155.26

Change

-2.93 (-1.85)%

Market Cap

USD 47.89B

Volume

1.47M

Avg Analyst Target

USD 161.00 (+3.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

+3.95 (+0.65%)

USD239.33B 28.18 19.52
DHR Danaher Corporation

-1.69 (-0.55%)

USD219.33B 38.94 26.42
DHR-PA Danaher Corporation

N/A

USD189.70B 261.66 N/A
IQV IQVIA Holdings Inc

-1.80 (-0.70%)

USD49.15B 65.47 24.01
MTD Mettler-Toledo International I..

-8.69 (-0.59%)

USD34.00B 58.23 34.38
LH Laboratory Corporation of Amer..

-3.07 (-1.08%)

USD27.10B 14.45 6.59
PKI PerkinElmer Inc

-3.19 (-1.80%)

USD22.33B 16.83 13.16
WAT Waters Corporation

-0.89 (-0.25%)

USD22.22B 34.22 24.53
CRL Charles River Laboratories Int..

+0.24 (+0.06%)

USD21.66B 55.50 28.22
DGX Quest Diagnostics Incorporated

-1.56 (-1.07%)

USD17.85B 8.75 6.36

ETFs Containing A

Symbol Name Weight Mer Price(Change) Market Cap
HIG:CA Brompton Global Healthcar.. 0.00 % 0.97 %

-0.03 (-0.28%)

USD0.05B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

-0.32 (-1.48%)

USD0.25B
XRMU:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

-0.15 (-0.39%)

USD0.11B
XRSS:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

-2.00 (-0.07%)

USD0.11B
XRSM:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

-0.15 (-0.45%)

USD0.11B
ZGEN:CA BMO MSCI Genomic Innovati.. 0.00 % 0.00 %

-0.48 (-1.63%)

N/A
MJJ MicroSectors Cannabis ETN.. 0.00 % 0.70 %

-0.95 (-1.29%)

N/A
MJO MicroSectors Cannabis 2X .. 0.00 % 0.95 %

-2.14 (-2.58%)

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.68 %

-0.34 (-1.87%)

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.23 (-1.81%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.03% 56% F 79% C+
Dividend Return 0.65% 57% F 14% F
Total Return 31.69% 61% D- 78% C+
Trailing 12 Months  
Capital Gain 52.72% 72% C- 73% C
Dividend Return 0.76% 67% D+ 10% F
Total Return 53.49% 72% C- 71% C-
Trailing 5 Years  
Capital Gain 259.23% 62% D- 94% A
Dividend Return 7.58% 80% B- 22% F
Total Return 266.81% 77% C+ 94% A
Average Annual (5 Year Horizon)  
Capital Gain 27.51% 61% D- 87% B+
Dividend Return 0.94% 75% C 22% F
Total Return 28.45% 72% C- 86% B
Risk Return Profile  
Volatility (Standard Deviation) 23.84% 56% F 49% F
Risk Adjusted Return 119.30% 83% B 95% A
Market Capitalization 47.89B 76% C 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.31 40% F 15% F
Price/Book Ratio 9.67 25% F 10% F
Price / Cash Flow Ratio 52.00 12% F 7% F
EV/EBITDA 31.03 17% F 14% F
Management Effectiveness  
Return on Equity 19.95% 65% D 71% C-
Return on Invested Capital 10.05% 56% F 77% C+
Return on Assets 8.35% 67% D+ 89% B+
Debt to Equity Ratio 46.87% 71% C- 64% D
Technical Ratios  
Short Ratio 2.03 88% B+ 53% F
Short Percent 0.96% 81% B- 79% C+
Beta 1.04 44% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.